Hutchmed to receive $10m milestone payment from partner Takeda
The AIM-traded company said the recommendation was the first of its kind for the treatment of previously treated metastatic colorectal cancer (CRC) in Europe. CRC is the second leading cause of cancer-related deaths on the continent. Fruzaqla was approved …